June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The Relative Odds of Progressing by Structural and Functional Tests in Glaucoma
Author Affiliations & Notes
  • Amir Marvasti
    Ophthalmology, University of California, San Diego, San Diego, CA
  • Linda M Zangwill
    Ophthalmology, University of California, San Diego, San Diego, CA
  • Ricardo Y Abe
    Ophthalmology, University of California, San Diego, San Diego, CA
    Department of Ophthalmology, University of Campinas, Campinas, Brazil
  • Alberto Diniz-Filho
    Ophthalmology, University of California, San Diego, San Diego, CA
    Department of Ophthalmology and Otorhinolaryngology, Federal University of Minas Gerais, Belo Horizonte, Belo Horizonte, Brazil
  • Carolina Gracitelli
    Ophthalmology, University of California, San Diego, San Diego, CA
    Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil
  • Robert N Weinreb
    Ophthalmology, University of California, San Diego, San Diego, CA
  • Christopher A Girkin
    Ophthalmology, University of Alabama, Birmingham, AL
  • Jeffrey M Liebmann
    Ophthalmology, New York Eye and Ear Infirmary, New York, NY
  • Felipe A Medeiros
    Ophthalmology, University of California, San Diego, San Diego, CA
  • Footnotes
    Commercial Relationships Amir Marvasti, None; Linda Zangwill, Carl Zeiss Meditec Inc (F), Heidelberg Engineering GmbH (F), Nidek Inc (F), Optovue Inc (F), Quark (F), Topcon Inc (F); Ricardo Abe, None; Alberto Diniz-Filho, None; Carolina Gracitelli, None; Robert Weinreb, Amatek (C), Nidek (F), Optovue (F), Aerie (F), Alcon (C), Allergan (C), Aquesys (C), Bausch & Lomb (C), Carl Zeiss Meditec Inc (F), Carl Zeiss Meditec, Inc. (C), Genentech (R), Quark (F), Topcon (F), Valeant (C); Christopher Girkin, Carl Zeiss Meditech, Inc. (F), EyeSight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F), SOLX (F); Jeffrey Liebmann, Alcon, Inc. (C), Allergan, Inc. (C), Bausch & Lomb, Inc. (C), Bausch & Lomb, Inc. (F), Carl Zeiss Meditech, Inc. (F), Diopysis, Inc. (C), Diopysis, Inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Pharmaceuticals, Inc. (C), Optovue, Inc. (F), Quark Pharmaceuticals, Inc (F), Reichert, Inc. (F), Sensimed, Inc. (F), Topcon, Inc. (F), Valeant Pharmaceuticals (C); Felipe Medeiros, Alcon Laboratories Inc (F), Alcon Laboratories Inc. (C), Alcon Laboratories Inc. (R), Allergan Inc (C), Allergan Inc (F), Allergan Inc (R), Bausch & Lomb (F), Carl Zeiss Meditec Inc. (C), Carl Zeiss Meditec Inc. (F), Carl Zeiss Meditec Inc. (R), Heidelberg Engineering Inc (F), Merck (F), National Eye Institute (F), Novartis (C), Reichert, Inc (F), Reichert, Inc (R), Sensimed (F), Topcon Inc (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 623. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amir Marvasti, Linda M Zangwill, Ricardo Y Abe, Alberto Diniz-Filho, Carolina Gracitelli, Robert N Weinreb, Christopher A Girkin, Jeffrey M Liebmann, Felipe A Medeiros; The Relative Odds of Progressing by Structural and Functional Tests in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):623.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the relationship between disease severity, number of tests during follow-up and the odds of progressing by structural and functional tests in glaucoma.

 
Methods
 

This was an observational cohort study involving 451 eyes of 303 patients with glaucomatous optic neuropathy and 110 eyes of 59 healthy subjects. Subjects were followed for an average of 3.6 ± 0.9 years with an average of 7.7 ± 2.4 visits. At each visit during follow-up, subjects underwent visual field assessment by standard automated perimetry (SAP) with Swedish interactive threshold algorithm (SITA Standard 24-2) and retinal nerve fiber layer (RNFL) evaluation by spectral domain optical coherence tomography (Spectralis SDOCT, Heidelberg Engineering). Slopes of change were calculated for SAP mean sensitivity (MS) and SDOCT average RNFL thickness. To ensure matched specificities and to take into account age-related changes, quantile regression of longitudinal data from healthy eyes was used to obtain cut-off values for age-related expected rates of change for each test. Progression by each test for glaucoma eyes was determined if the slope of change was statistically significant and exceed the 95% confidence limit cut-offs. A logistic regression model was then used to evaluate factors associated with the relative odds of progressing by SDOCT versus SAP. The model adjusted for age and variability (standard error of slope) of SAP and SDOCT.

 
Results
 

There were statistically significant effects of the number of tests, baseline disease severity and an interaction between these two variables on the odds of progressing by structure versus function. The odds of progressing by SDOCT were significantly higher than by SAP for a lower number of tests and at early stages of disease (Figure 1). For moderate and advanced stages of disease, the odds of progressing by SAP were higher than by SDOCT, but only if a relatively large number of tests were acquired during follow-up.

 
Conclusions
 

The relative odds of identifying progression by structural and functional tests varied with the number of tests acquired during follow-up and the stage of the disease.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×